AstraZeneca PLC (AZN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AstraZeneca PLC (AZN) has a cash flow conversion efficiency ratio of 0.071x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX3.36 Billion ≈ $408.69K USD) by net assets (GBX47.38 Billion ≈ $5.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of AstraZeneca PLC to measure how much of total assets are equity-financed.
AstraZeneca PLC - Cash Flow Conversion Efficiency Trend (1990–2025)
This chart illustrates how AstraZeneca PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of AstraZeneca PLC to evaluate the quality of earnings relative to operating cash generation.
AstraZeneca PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AstraZeneca PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MOBVISTA INC. DL-01
F:6MO
|
N/A |
|
Pengxin International Mining Co Ltd
SHG:600490
|
0.073x |
|
Insignia Financial Ltd
AU:IFL
|
0.091x |
|
Odfjell Drilling Ltd
OL:ODL
|
0.081x |
|
Xuzhou Handler Special Vehicle Co Ltd
SHE:300201
|
0.029x |
|
Pandox AB (publ)
ST:PNDX-B
|
0.016x |
|
LEROY SEAFOOD GR.UNSP.ADR
F:Z1L0
|
0.031x |
|
Ningbo ZhongDa Leader Intelligent Transmission Co Ltd
SHE:002896
|
0.021x |
Annual Cash Flow Conversion Efficiency for AstraZeneca PLC (1990–2025)
The table below shows the annual cash flow conversion efficiency of AstraZeneca PLC from 1990 to 2025. For the full company profile with market capitalisation and key ratios, see AZN market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | GBX48.72 Billion ≈ $5.93 Million |
GBX14.57 Billion ≈ $1.77 Million |
0.299x | +3.09% |
| 2024-12-31 | GBX40.87 Billion ≈ $4.97 Million |
GBX11.86 Billion ≈ $1.44 Million |
0.290x | +9.87% |
| 2023-12-31 | GBX39.17 Billion ≈ $4.77 Million |
GBX10.35 Billion ≈ $1.26 Million |
0.264x | -0.20% |
| 2022-12-31 | GBX37.06 Billion ≈ $4.51 Million |
GBX9.81 Billion ≈ $1.19 Million |
0.265x | +74.37% |
| 2021-12-31 | GBX39.29 Billion ≈ $4.78 Million |
GBX5.96 Billion ≈ $725.52K |
0.152x | -50.54% |
| 2020-12-31 | GBX15.64 Billion ≈ $1.90 Million |
GBX4.80 Billion ≈ $583.90K |
0.307x | +50.87% |
| 2019-12-31 | GBX14.60 Billion ≈ $1.78 Million |
GBX2.97 Billion ≈ $361.24K |
0.203x | +9.12% |
| 2018-12-31 | GBX14.04 Billion ≈ $1.71 Million |
GBX2.62 Billion ≈ $318.53K |
0.186x | -13.30% |
| 2017-12-31 | GBX16.64 Billion ≈ $2.02 Million |
GBX3.58 Billion ≈ $435.34K |
0.215x | -13.54% |
| 2016-12-31 | GBX16.67 Billion ≈ $2.03 Million |
GBX4.14 Billion ≈ $504.33K |
0.249x | +37.96% |
| 2015-12-31 | GBX18.44 Billion ≈ $2.24 Million |
GBX3.32 Billion ≈ $404.43K |
0.180x | -49.83% |
| 2014-12-31 | GBX19.65 Billion ≈ $2.39 Million |
GBX7.06 Billion ≈ $858.75K |
0.359x | +12.89% |
| 2013-12-31 | GBX23.25 Billion ≈ $2.83 Million |
GBX7.40 Billion ≈ $900.37K |
0.318x | +9.71% |
| 2012-12-31 | GBX23.95 Billion ≈ $2.91 Million |
GBX6.95 Billion ≈ $845.37K |
0.290x | -12.94% |
| 2011-12-31 | GBX23.47 Billion ≈ $2.86 Million |
GBX7.82 Billion ≈ $951.59K |
0.333x | -26.96% |
| 2010-12-31 | GBX23.41 Billion ≈ $2.85 Million |
GBX10.68 Billion ≈ $1.30 Million |
0.456x | -19.08% |
| 2009-12-31 | GBX20.82 Billion ≈ $2.53 Million |
GBX11.74 Billion ≈ $1.43 Million |
0.564x | +3.58% |
| 2008-12-31 | GBX16.06 Billion ≈ $1.95 Million |
GBX8.74 Billion ≈ $1.06 Million |
0.544x | +8.11% |
| 2007-12-31 | GBX14.91 Billion ≈ $1.81 Million |
GBX7.51 Billion ≈ $913.75K |
0.504x | +0.90% |
| 2006-12-31 | GBX15.42 Billion ≈ $1.88 Million |
GBX7.69 Billion ≈ $936.02K |
0.499x | +1.32% |
| 2005-12-31 | GBX13.69 Billion ≈ $1.67 Million |
GBX6.74 Billion ≈ $820.43K |
0.493x | +46.52% |
| 2004-12-31 | GBX14.50 Billion ≈ $1.76 Million |
GBX4.87 Billion ≈ $592.90K |
0.336x | +30.45% |
| 2003-12-31 | GBX13.26 Billion ≈ $1.61 Million |
GBX3.42 Billion ≈ $415.63K |
0.258x | -40.17% |
| 2002-12-31 | GBX11.22 Billion ≈ $1.37 Million |
GBX4.83 Billion ≈ $588.04K |
0.431x | +53.24% |
| 2001-12-31 | GBX9.63 Billion ≈ $1.17 Million |
GBX2.71 Billion ≈ $329.30K |
0.281x | +14.89% |
| 2000-12-31 | GBX9.55 Billion ≈ $1.16 Million |
GBX2.34 Billion ≈ $284.22K |
0.245x | +178.60% |
| 1999-12-31 | GBX10.35 Billion ≈ $1.26 Million |
GBX908.55 Million ≈ $110.54K |
0.088x | +9.62% |
| 1998-12-31 | GBX10.98 Billion ≈ $1.34 Million |
GBX879.74 Million ≈ $107.04K |
0.080x | -61.15% |
| 1997-12-31 | GBX3.62 Billion ≈ $440.89K |
GBX747.21 Million ≈ $90.91K |
0.206x | -4.16% |
| 1996-12-31 | GBX3.66 Billion ≈ $445.48K |
GBX787.75 Million ≈ $95.85K |
0.215x | +11.55% |
| 1995-12-31 | GBX3.04 Billion ≈ $369.44K |
GBX585.64 Million ≈ $71.25K |
0.193x | -15.95% |
| 1994-12-31 | GBX2.73 Billion ≈ $331.56K |
GBX625.36 Million ≈ $76.09K |
0.229x | -24.42% |
| 1993-12-31 | GBX2.32 Billion ≈ $282.74K |
GBX705.58 Million ≈ $85.85K |
0.304x | -75.00% |
| 1992-12-31 | GBX169.87 Million ≈ $20.67K |
GBX206.27 Million ≈ $25.10K |
1.214x | +120.37% |
| 1991-12-31 | GBX916.88 Million ≈ $111.56K |
GBX505.22 Million ≈ $61.47K |
0.551x | -53.33% |
| 1990-12-31 | GBX682.84 Million ≈ $83.08K |
GBX806.30 Million ≈ $98.10K |
1.181x | -- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splend… Read more